MV Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.06M | Buy |
7,581
+13
| +0.2% | +$1.82K | 0.1% | 93 |
|
|
2025
Q4 | $929K | Buy |
7,568
+7
| +0.1% | +$851 | 0.09% | 99 |
|
|
2025
Q3 | $839K | Hold |
7,561
| – | – | 0.08% | 104 |
|
|
2025
Q2 | $838K | Sell |
7,561
-2
| -0% | -$213 | 0.09% | 103 |
|
|
2025
Q1 | $847K | Buy |
7,563
+1,297
| +21% | +$134K | 0.09% | 98 |
|
|
2024
Q4 | $579K | Sell |
6,266
-26
| -0.4% | -$2.34K | 0.06% | 108 |
|
|
2024
Q3 | $528K | Buy |
6,292
+93
| +2% | +$7.1K | 0.06% | 114 |
|
|
2024
Q2 | $425K | Sell |
6,199
-404
| -6% | -$27K | 0.05% | 121 |
|
|
2024
Q1 | $484K | Sell |
6,603
-57
| -0.9% | -$4.38K | 0.06% | 116 |
|
|
2023
Q4 | $540K | Buy |
6,660
+56
| +0.8% | +$4.36K | 0.07% | 111 |
|
|
2023
Q3 | $495K | Buy |
6,604
+268
| +4% | +$20.6K | 0.07% | 111 |
|
|
2023
Q2 | $488K | Buy |
6,336
+139
| +2% | +$11.1K | 0.06% | 110 |
|
|
2023
Q1 | $514K | Buy |
6,197
+237
| +4% | +$19.6K | 0.07% | 104 |
|
|
2022
Q4 | $512K | Buy |
5,960
+42
| +0.7% | +$3.33K | 0.08% | 89 |
|
|
2022
Q3 | $365K | Buy |
5,918
+203
| +4% | +$12.8K | 0.06% | 98 |
|
|
2022
Q2 | $353K | Buy |
5,715
+79
| +1% | +$4.89K | 0.06% | 109 |
|
|
2022
Q1 | $335K | Sell |
5,636
-121
| -2% | -$7.74K | 0.05% | 114 |
|
|
2021
Q4 | $418K | Sell |
5,757
-6
| -0.1% | -$413 | 0.06% | 108 |
|
|
2021
Q3 | $403K | Buy |
5,763
+198
| +4% | +$13.9K | 0.07% | 102 |
|
|
2021
Q2 | $383K | Buy |
5,565
+166
| +3% | +$11.1K | 0.07% | 100 |
|
|
2021
Q1 | $349K | Buy |
5,399
+30
| +0.6% | +$1.93K | 0.06% | 95 |
|
|
2020
Q4 | $313K | Hold |
5,369
| – | – | 0.06% | 92 |
|
|
2020
Q3 | $339K | Buy |
5,369
+100
| +2% | +$6.93K | 0.07% | 81 |
|
|
2020
Q2 | $405K | Buy |
5,269
+203
| +4% | +$15.6K | 0.1% | 74 |
|
|
2020
Q1 | $379K | Buy |
5,066
+200
| +4% | +$13.8K | 0.1% | 74 |
|
|
2019
Q4 | $316K | Sell |
4,866
-5,484
| -53% | -$357K | 0.07% | 89 |
|
|
2019
Q3 | $656K | Buy |
10,350
+498
| +5% | +$32.6K | 0.15% | 64 |
|
|
2019
Q2 | $666K | Buy |
9,852
+678
| +7% | +$44.6K | 0.15% | 60 |
|
|
2019
Q1 | $596K | Buy |
9,174
+4,308
| +89% | +$286K | 0.14% | 59 |
|
|
2018
Q4 | $304K | Sell |
4,866
-2,262
| -32% | -$158K | 0.09% | 74 |
|
|
2018
Q3 | $550K | Sell |
7,128
-34
| -0.5% | -$2.57K | 0.14% | 53 |
|
|
2018
Q2 | $507K | Sell |
7,162
-36
| -0.5% | -$2.54K | 0.13% | 52 |
|
|
2018
Q1 | $543K | Sell |
7,198
-162
| -2% | -$12.9K | 0.14% | 50 |
|
|
2017
Q4 | $527K | Sell |
7,360
-14
| -0.2% | -$1.06K | 0.14% | 53 |
|
|
2017
Q3 | $597K | Sell |
7,374
-234
| -3% | -$17.9K | 0.17% | 48 |
|
|
2017
Q2 | $538K | Sell |
7,608
-416
| -5% | -$27.7K | 0.16% | 53 |
|
|
2017
Q1 | $545K | Sell |
8,024
-76
| -0.9% | -$5.34K | 0.17% | 52 |
|
|
2016
Q4 | $580K | Sell |
8,100
-188
| -2% | -$14K | 0.21% | 44 |
|
|
2016
Q3 | $656K | Sell |
8,288
-441
| -5% | -$35.8K | 0.24% | 38 |
|
|
2016
Q2 | $728K | Buy |
8,729
+435
| +5% | +$38.6K | 0.26% | 35 |
|
|
2016
Q1 | $762K | Buy |
8,294
+311
| +4% | +$28K | 0.31% | 34 |
|
|
2015
Q4 | $808K | Buy |
7,983
+924
| +13% | +$96.1K | 0.32% | 40 |
|
|
2015
Q3 | $693K | Buy |
7,059
+513
| +8% | +$57K | 0.32% | 40 |
|
|
2015
Q2 | $766K | Buy |
6,546
+361
| +6% | +$39.4K | 0.31% | 41 |
|
|
2015
Q1 | $607K | Buy |
6,185
+253
| +4% | +$25.7K | 0.25% | 39 |
|
|
2014
Q4 | $559K | Buy |
+5,932
| New | +$614K | 0.25% | 37 |
|
Other funds holding GILD
VCM
VPM
MV Capital Management's GILD Position: Q1 2026 in Review
MV Capital Management increased its Gilead Sciences (GILD) stake by 0.17% in Q1 2026, buying an estimated $1.82K and bringing the position to 7,581 shares worth $1.06M. The position accounts for 0.1% of the portfolio, ranked #93.
MV Capital Management first reported a position in GILD in Q4 2014 and has held it in 46 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- MV Capital Management held 7,581 shares of Gilead Sciences worth $1.06M as of Q1 2026.
- MV Capital Management bought 13 Gilead Sciences shares in Q1 2026, an estimated $1.82K.
- Gilead Sciences made up 0.1% of MV Capital Management's portfolio in Q1 2026, its #93 holding.
- MV Capital Management first reported a position in Gilead Sciences in Q4 2014 and has held it in 46 quarters since.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on MV Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.